Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
The Sunshine Act puts physicians in the spotlight - NephrologyNews.com |
BALTIMORE––If you accept payments from manufacturers or pharmaceutical companies, that information will be shared with the public, thanks to the Sunshine Act. Lauren K. Roth, assistant general counsel for the industry group PhRMA, presented information on the Sunshine Act at the Renal Physicians Association's annual conference here. She said the Act uses “broadly defined” wording to constitute what might be considered a payment between a physician and a company. Applicable manufacturers are entities that operate in the United States and either 1) produce at least one “covered product” (basically, any prescription drug, device, biological or medical supply that is eligible for payment by Medicare, Medicaid, or CHIP), or 2) operate under common ownership with a manufacturer and provide assistance or support in the manufacture, marketing, promotion, sale or distribution of a covered product, explained Roth.
Reprints of articles, for example, that are provided to physician offices could be considered an open payment. If you are running for political office, and a pharmaceutical company donates to your campaign, that is considered a payment. The CMS Open Payments website includes the first reporting period from August-December 2013, covering 546 physicians. Future reports are due to be published every year in June and will include a full 12 months of payment data from the previous year. March 31 is the deadline each year for manufacturers to submit information on open payments to physicians. In the initial report, open payments varied widely; the lowest was $483.53, while the highest was $2.4 million paid to a physician from a medical device manufacturer.
|